XOMA Royalty reports 2025 net income $31.7M vs loss $13.8M; royalties up 68% YoY

XOMA Royalty Corp

Full-year cash receipts $50.5M ($33.6M royalties, +68% YoY; $16.9M milestones); Q4 net income $6.1M vs loss $4.0M YoY.
Repurchased 648,048 shares for $16.0M; completed seven acquisitions adding 22 assets to portfolio.
Pipeline catalysts: volixibat Phase 2b data in PSC in Q2 2026; ersodetug Phase 3 data in tumor HI 2H 2026.
Seralutinib Phase 3 PAH missed primary endpoint; path forward discussions with FDA ongoing.
Litigation vs Janssen over TREMFYA IP continues; G&A includes $1.1M legal costs in 2025.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

XOMA Royalty Corp reported financial results for the fiscal quarter and year ended December 31, 2025.

Period: the fiscal quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 18, 2026, XOMA Royalty Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

XOMA Royalty Corp filing history →

Source: SEC EDGAR

accession 0001193125-26-112338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.